GlassScriptPhysician profile
Laura Adler
NPI 1255890059
$18,398.75
in general payments reported to CMS, 2019-2025
28 companies · $955 in 2025
The $955 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $115 · 2021: $133 · 2022: $6,817 · 2023: $5,588 · 2024: $4,792 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,236 · Food and Beverage: $5,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,235.72 |
| Food and Beverage | $5,098.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries LP | $6,552.86 | 2022-2024 | |
| Stryker Corporation | $5,286.45 | 2022-2025 | Prophecy, Prostep, Salvation |
| Integra Lifesciences Corporation | $1,776.54 | 2023-2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Biotissue Holdings INC. | $1,280.12 | 2022-2025 | |
| Paragon 28, INC. | $858.23 | 2022-2025 | Portfolio, Precision Mis Bunion, Total Talus |
| Zimmer Biomet Holdings, INC. | $703.04 | 2022 | |
| International Life Sciences | $543.75 | 2024 | Flexband |
| Orthofix Medical, INC. | $193.30 | 2023-2024 | Physio-Stim, Galaxy Fixation Gemini, Truelok Evo |
| Kerecis Limited | $179.20 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Solventum Corporation | $145.69 | 2024-2025 | V.A.C. Veraflo, Promogran Prisma, Activ.A.C. |
| Osteomed LLC | $114.94 | 2020 | |
| Abbvie INC. | $113.70 | 2021 | |
| Depuy Synthes Sales INC. | $101.94 | 2023 | Na, Fibergraft Aeridyan Matrix |
| Treace Medical Concepts, INC. | $84.34 | 2024-2025 | |
| Musculoskeletal Transplant Foundation INC. | $62.52 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Access Pro Medical, LLC | $52.44 | 2022-2025 | Matriderm |
| Amgen INC. | $50.78 | 2025 | Krystexxa |
| Organogenesis INC. | $50.72 | 2025 | Puraply Wound Matrix, Apligraf, Via Matrix |
| Polynovo North America LLC | $40.22 | 2024 | Novosorb Btm |
| Reprise Biomedical, INC. | $38.78 | 2023 | Miro3d |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.41 | 2023 | Jublia, Arazlo |
| Stimwave Technologies Incorporated | $24.83 | 2022 | |
| Smith+Nephew, INC. | $21.55 | 2023 | Collagenase Santyl, Regranex |
| Bioventus LLC | $20.84 | 2025 | Exogen Ultrasound Bone Healing System |
| Cerapedics INC. | $19.31 | 2021 | |
| Mimedx Group, INC. | $15.93 | 2024 | |
| Hartmann USA, INC. | $14.19 | 2025 | Zetuvit Plus 10x10 P10 |
| Boston Scientific Corporation | $14.13 | 2023 | Varithena Administration Pack |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Adler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.